Diffusion Pharmaceuticals... (DFFN)
4.40
0.41 (10.28%)
At close: Aug 16, 2023, 8:00 PM
10.28% (1D)
| Bid | n/a |
| Market Cap | 8.98M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.36B |
| EPS (ttm) | -7.11 |
| PE Ratio (ttm) | -0.6188466947960619 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 349,445 |
| Avg. Volume (20D) | 47,812 |
| Open | 4.23 |
| Previous Close | 3.99 |
| Day's Range | 4.17 - 5.19 |
| 52-Week Range | 4.14 - 14.37 |
| Beta | 1.76 |
About DFFN
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia....
Industry Biotechnology
Sector Healthcare
IPO Date May 23, 2008
Employees 13
Stock Exchange NASDAQ
Ticker Symbol DFFN
Website https://www.diffusionpharma.com